Loefflers syndrome differential diagnosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 11: | Line 11: | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! colspan="2" rowspan="4" |Diseases | ! colspan="2" rowspan="4" |Diseases | ||
| colspan=" | | colspan="4" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
! colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ! colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | | colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
|- | |- | ||
| colspan=" | | colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | ||
! colspan=" | ! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ||
|- | |- | ||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
Line 25: | Line 25: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2 | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2 | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased Eosinophil | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased Eosinophil | ||
count | count | ||
Line 49: | Line 47: | ||
Fever | Fever | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 78: | Line 74: | ||
eosinophilia | eosinophilia | ||
| style="background: #F5F5F5; padding: 5px;" |cough, breathlessness, wheezing, fatigue, and fever. | | style="background: #F5F5F5; padding: 5px;" |cough, breathlessness, wheezing, fatigue, and fever. | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 118: | Line 112: | ||
* Hemoptysis | * Hemoptysis | ||
* Wheezing | * Wheezing | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 147: | Line 139: | ||
periorbital edema, myositis, and eosinophilia ('''Trichinellosis)''' | periorbital edema, myositis, and eosinophilia ('''Trichinellosis)''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 174: | Line 164: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary parenchymal invasion | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary parenchymal invasion | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 198: | Line 186: | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis | ||
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure | | rowspan="2" style="background: #F5F5F5; padding: 5px;" |Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 213: | Line 199: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycobacterium tuberculosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycobacterium tuberculosis | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 231: | Line 215: | ||
* Asthma, | * Asthma, | ||
* Skin, cardiovascular, gastrointestinal, renal, and neurologic systems may also be involved. | * Skin, cardiovascular, gastrointestinal, renal, and neurologic systems may also be involved. | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 260: | Line 242: | ||
* asymptomatic pulmonary infiltration with eosinophils, chronic cough with or without dyspnea and fever, acute eosinophilic pneumonia, and | * asymptomatic pulmonary infiltration with eosinophils, chronic cough with or without dyspnea and fever, acute eosinophilic pneumonia, and | ||
* DRESS should be suspected when the patient has a skin eruption, fever, facial edema, enlarged lymph nodes, and a history of initiation of a culprit medication two to six weeks prior to disease onset | * DRESS should be suspected when the patient has a skin eruption, fever, facial edema, enlarged lymph nodes, and a history of initiation of a culprit medication two to six weeks prior to disease onset | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 287: | Line 267: | ||
* Following radiation therapy for breast cancer | * Following radiation therapy for breast cancer | ||
* Cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases | * Cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 319: | Line 297: | ||
an acute febrile illness of less than seven days' duration, characterized by a nonproductive cough, dyspnea, | an acute febrile illness of less than seven days' duration, characterized by a nonproductive cough, dyspnea, | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 344: | Line 320: | ||
!Symptom 1 | !Symptom 1 | ||
! colspan="1" rowspan="1" |Symptom 2 | ! colspan="1" rowspan="1" |Symptom 2 | ||
!Physical exam 1 | !Physical exam 1 | ||
! colspan="1" rowspan="1" |Physical exam 2 | ! colspan="1" rowspan="1" |Physical exam 2 | ||
!Increased Eosinophil count | !Increased Eosinophil count | ||
(High) | (High) | ||
Line 359: | Line 333: | ||
| | | | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoidosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoidosis | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 375: | Line 347: | ||
| | | | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary Langerhans cell histiocytosis (Histiocytosis X) | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary Langerhans cell histiocytosis (Histiocytosis X) | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 391: | Line 361: | ||
| | | | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic pulmonary fibrosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic pulmonary fibrosis | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 407: | Line 375: | ||
| | | | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 7 | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 7 | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 17:00, 21 May 2019
![](/images/1/16/Home_logo1.png)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Loeffler syndrome must be differentiated from other diseases that cause pulmonary eosinophilia, such as Churg-Strauss, drug and toxin-induced eosinophilic lung diseases, other helminthic and fungal infection related eosinophilic lung diseases, and nonhelminthic infections such as Coccidioidomycosis, and Mycobacterium tuberculosis.
Differentiating Loeffler syndrome from other pulmonary eosinophilia syndromes on the basis of etiology.
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||
Physical exam 2 | Increased Eosinophil
count |
Other lab findings | CXR | CT Scan | ||||||||
Helminthic
and fungal infection-related eosinophilic lung diseases |
Transpulmonary
passage of larvae (Loffler's syndrome) |
Cough
Sputum production Wheezing Fever |
|
| ||||||||
Tropical
pulmonary eosinophilia |
cough, breathlessness, wheezing, fatigue, and fever. |
|
|
|
| |||||||
Allergic bronchopulmonary aspergillosis |
|
Mild to moderate |
|
|
||||||||
Heavy
hematogenous seeding with helminths |
depends on the organism for example:
periorbital edema, myositis, and eosinophilia (Trichinellosis) |
Mild to
moderate to high |
|
|
| |||||||
Pulmonary parenchymal invasion |
|
|
|
|
| |||||||
Nonhelminthic infections | Coccidioidomycosis | Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure |
|
|||||||||
Mycobacterium tuberculosis | ||||||||||||
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) |
|
|
|
|
|
|||||||
Drug- and toxin-induced eosinophilic lung diseases |
|
Mild to moderate |
| |||||||||
Chronic eosinophilic pneumonia |
|
|
|
|
||||||||
Idiopathic acute eosinophilic pneumonia | apid development of acute respiratory failure in a previously healthy patient.
often associated with recent initiation or resumption of cigarette smoking, and less commonly with heavy inhalational exposure to smoke, fine sand, or dust. an acute febrile illness of less than seven days' duration, characterized by a nonproductive cough, dyspnea, |
|
|
|
Often associated with recent initiation or resumption of cigarette smoking, and less commonly with heavy inhalational exposure to smoke, fine sand, or dust | |||||||
Diseases | Symptom 1 | Symptom 2 | Physical exam 1 | Physical exam 2 | Increased Eosinophil count
(High) |
Other lab findings | CXR | CT Scan | Histopathology | Gold standard | Additional findings | |
Sarcoidosis | Mild to moderate | |||||||||||
Pulmonary Langerhans cell histiocytosis (Histiocytosis X) | Mild to moderate | |||||||||||
Idiopathic pulmonary fibrosis | <10 percent | |||||||||||
Differential Diagnosis 7 |